Identification of a novel miRNA-based recurrence and prognosis prediction biomarker for hepatocellular carcinoma

Xuanfeng Zhang¹, Dong Zhang¹,², Xuefeng Bu³, Xinhui Zhang* and Long Cui¹*

Introduction

Hepatocellular carcinoma (HCC) is the sixth most common and the third deadliest malignant tumor globally [1]. The tumorigenic process of HCC is related to hepatitis virus infection, alcoholic liver cirrhosis, and nonalcoholic fatty liver disease [2]. Surgical resection, which can significantly prolong the survival time of patients, is still the best choice for patients with early or advanced HCC [3]. In addition, liver transplantation (LT) is considered to be an option for treatment of liver cancer. Because LT has the ability to cure liver disease, it is a better choice in certain circumstances (e.g., small hepatocellular carcinoma) [4]. Radiotherapy, radiofrequency ablation (RFA), and transcatheter arterial chemoembolization (TACE) are options for patients with liver cancer.

Abstract

Background: A high recurrence rate has always been a serious problem for treatment of hepatocellular carcinoma (HCC). Exploring predictors of postoperative and post-transplantation recurrence in patients with HCC can guide treatment strategies for clinicians.

Results: In this study, logistic regression and multivariate Cox regression models were constructed with microRNA expression profile data from The Cancer Genome Atlas (TCGA) and gene expression omnibus (GEO). The accuracy of predictions was assessed using receiver operating characteristic curve (ROC) and Kaplan–Meier survival curve analyses. The results showed that the combination of 10 miRNAs (including hsa-miR-509-3p, hsa-miR-769-3p, hsa-miR-671-3p, hsa-miR-296-5p, hsa-miR-767-5p, hsa-miR-421, hsa-miR-193a-3p, hsa-miR-139-3p, hsa-miR-342-3p, and hsa-miR-193a-5p) accurately predicted postoperative and post-transplantation malignancy recurrence in HCC patients and was also valuable for prognostic evaluation of HCC patients. The 10-miRNA prediction model might assist doctors in making prognoses for HCC patients who have a high probability of relapse following surgery and in offering additional, individualized treatment to lessen that risk.

Keywords: Hepatocellular Carcinoma, Recurrence, Prognosis

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Zhang et al. BMC Bioinformatics (2022) 23:479
https://doi.org/10.1186/s12859-022-05040-y

BMC Bioinformatics
who cannot undergo resection and liver transplantation [5]. All these treatments have significantly improved the prognosis of patients with HCC.

Despite extension of the overall survival of HCC, postoperative recurrence still has a serious impact on these patients. Postoperative recurrence of HCC mainly includes two types, intrahepatic metastasis (IM) and multicenter occurrence (MO) [6]. The tumor recurrence rate at 5 years after liver resection can reach 70% [7]. However, patients face the same problem after liver transplantation, especially recipients whose tumor burden exceeds liver transplantation criteria [8]. Patients who experience relapse have worse prognosis and shorter survival, with a median survival of approximately 9 to 16 months [9]. Finding predictors of HCC recurrence can guide clinicians in the choice of treatment for patients postresection and posttransplantation.

However, most of the current research focuses on the prediction of the prognosis of patients with HCC, and the number of studies related to the prediction of liver cancer recurrence is relatively small. Some researchers have been paying attention to the assessment of recurrence of HCC patients, and have used mRNAs to build a prediction model of recurrence of HCC patients [10]. We believed that miRNAs have unique advantages in humoral assays compared to mRNAs. Some researchers have the same idea as us. They constructed a miRNA-based liver cancer recurrence prediction model. The variable screening method used was univariate Cox analysis, and the modeling method was multivariate Cox analysis [11]. On this basis, we designed an innovative variable screening method (not just the common Cox regression analysis and Lasso regression analysis) to establish a Logistic classification-based model for predicting HCC recurrence in postresection and posttransplantation HCC patients. Internal and external validations showed that this is a stable method for predicting tumor recurrence in HCC patients.

**Method**

**Data collection and processing**

RNA-seq data of miRNA mature strand expression (Cancer Genome Atlas liver cancer, LIHC) were downloaded from UCSC xena (http://xena.ucsc.edu/) and normalized to log(RPM + 1). ChIP data (GSE30297) of miRNA mature strand expression were downloaded from GEO (https://www.ncbi.nlm.nih.gov/geo/). LIHC was used for training and internal validation and GSE30297 for recurrence external validation. To avoid bias in calculating risk scores, we removed miRNAs expressed at relatively low levels in all samples. This data processing was performed using R software (version 4.2.0).

**Training set splitting and variable selection**

The LIHC cohort was divided into a training dataset (60%) and an internal validation dataset (40%). The LIHC training dataset was used for recurrence and survival prediction model construction. Collinearity was removed using LASSO regression analysis. We reset the lambda value in the LASSO program and reduced the number of miRNAs included in the analysis to 10. This process was carried out in R software, and the survival (version 3.1.1) and glmnet (version 4.1.4) R packages were used.
Gaussian mixture model for further variable screening

All chosen miRNAs were merged, permuted, and modeled using logistic regression analysis. The AUC was computed individually for each model. The classification used model-based hierarchical agglomerative clustering, which is based on a Gaussian finite mixture model, and the AUC value was used as the classification basis. The mclust R package (version 5.4.9) was utilized for model-based clustering, classification, and density estimation based on finite normal mixture modeling.

Predictive model generation

Recurrence prediction models were established using logistic regression, and prognostic models were established using multivariate Cox regression. Model building was performed with the LIHC training dataset.

Data visualization

ROC curves were used to demonstrate model discrimination, and Kaplan–Meier curves were used to demonstrate the relationship between miRNA expression and overall or disease-free survival. The miRNA expression heatmap was displayed using the pheatmap package (version 1.0.12). Functional analysis was performed using clusterProfiler (version 4.4.2), and the results were visualized using gglopt2 (version 3.3.5).

Statistical analysis

R software was used for all statistical analyses (version 4.2.0). Logistic regression was utilized to predict tumor recurrence. Cox regression and Kaplan–Meier analysis were employed in the survival study. We performed t tests for paired samples. A p value of 0.05 or less was used to determine significance in all statistical tests.

Result

Variable filtering

Previous studies have tended to use differentially expressed genes to screen for molecules that may be associated with worse prognosis, such as recurrence, in HCC patients. We believe that prognostic or recurrence-related genes should be differentially expressed in different risk groups of tumors and not in tumors or normal tissues. Therefore, we included all mature miRNAs in the first step of variable screening. A total of 90 miRNAs were obtained after taking the intersection of LIHC, GSE30297, and GSE31384 data and deleting miRNAs with low expression (Fig. 1A). The characteristics of the three datasets (e.g., sample size, platform) are shown in Table 1. As depicted in Fig. 1A, after we reset the lambda parameters in LASSO regression, a total of 10 miRNAs were identified for further analysis (hsa-miR-509-3p, hsa-miR-769-3p, hsa-miR-671-3p, hsa-miR-296-5p, hsa-miR-767-5p, hsa-miR-421, hsa-miR-193a-3p, hsa-miR-139-3p, hsa-miR-342-3p, and hsa-miR-193a-5p). The expression levels of these 10 candidate miRNAs in the three datasets are shown in Fig. 2.

Gaussian mixture model for further variable screening

We performed classification using a Gaussian finite mixture model to further fit the model and more precisely estimate recurrence (Fig. 1A). A total of 1023 logistic
Fig. 1 Workflow of this study

Table 1 Characteristics of the datasets involved in this study

| Dataset                                    | Number of samples | Clinical features     | Application           | Platform      |
|--------------------------------------------|-------------------|-----------------------|-----------------------|---------------|
| TCGA mature strand expression              |                   |                       |                       |               |
| TCGA liver cancer (LIHC)                   | 420               | Recurrence and survival | Training and validation | RNA-seq       |
| GSE30297                                   | 97                | Recurrence            | Validation            | GPL8786       |
regression models were produced after the permutation and combination of 10 miRNAs. All logistic regression models were divided into 9 clusters. Among them, the cluster in the upper right corner of Fig. 3 had the highest AUC value. The NO.1023 model, i.e., the model incorporating all 10 miRNAs, had the largest AUC value (AUC = 0.75). The Gaussian mixture model further determined that among all models, that incorporating all 10 miRNAs had the best predictive capability.

**Logistic regression for recurrence prediction**

The LIHC cohort was randomly divided into 2 groups (60% TCGA training set and 40% TCGA validation set). The logistic regression model development process used the 60% TCGA training set. The results showed that the combination of hsa-miR-509-3p (coef = −0.378, P = 0.09), hsa-miR-769-3p (coef = −0.857, P = 0.01), hsa-miR-671-3p (coef = 0.881, P = 0.009), hsa-miR-296-5p (coef = −0.219, P = 0.137),
hsa-miR-767-5p \( (\text{coef} = -0.128, P = 0.08) \), hsa-miR-421 \( (\text{coef} = -0.152, P = 0.58) \), hsa-miR-193a-3p \( (\text{coef} = 0.412, P = 0.25) \), hsa-miR-139-3p \( (\text{coef} = -0.356, P = 0.04) \), hsa-miR-342-3p \( (\text{coef} = 0.463, P = 0.02) \), and hsa-miR-193a-5p \( (\text{coef} = 0.412, P = 0.28) \) comprised a tumor recurrence predictor for HCC patients. Recurrence is associated with the disease-free interval (DFI) in malignancy. The relationship between the 10 miRNAs and DFI is demonstrated in Fig. 4A, where expression of hsa-miR-139-3p, hsa-miR-296-5p, hsa-miR-342-3p, hsa-miR-509-3p, and hsa-miR-769-3p correlated positively with DFI and that of hsa-miR-193a-3p, hsa-miR-421, hsa-miR-671-3p, and hsa-miR-767-5p correlated negatively.

To further validate the recurrence predictive capability of these 10 miRNAs, logistic regression risk scores were calculated using the following formula: the combination miRNA panel = \((-0.378 \times \text{expression of hsa-miR-509-3p}) + (-0.857 \times \text{expression of hsa-miR-769-3p}) + (0.881 \times \text{expression of hsa-miR-671-3p}) + (-0.219 \times \text{expression of hsa-miR-296-5p}) + (-0.128 \times \text{expression of hsa-miR-767-5p}) + (-0.152 \times \text{expression of hsa-miR-421}) + (0.412 \times \text{expression of hsa-miR-193a-3p}) + (-0.356 \times \text{expression of hsa-miR-139-3p}) + (0.463 \times \text{expression of hsa-miR-342-3p}) + (0.412 \times \text{expression of hsa-miR-193a-5p})\). The combination of 10 miRNAs in the training dataset from TCGA had the highest AUC value (AUC = 0.751) compared to individual miRNAs.
Fig. 5 Predictive ability of the combination of 10 miRNAs for postoperative recurrence and posttransplantation recurrence in HCC patients. 

A ROC curves of the 10-miRNA combination and individual miRNAs in the training dataset from TCGA. 
B ROC curves of the 10-miRNA combination and individual miRNAs in the validation dataset from TCGA. 
C ROC curves of the 10-miRNA combination and individual miRNAs in the GSE30297 post translation recurrence validation dataset. 
D ROC curves of the 10-miRNA combination in the training and validation datasets. 
E Kaplan–Meier analysis of the disease-free interval (DFI) in the training dataset from TCGA. 
F Kaplan–Meier analysis of overall survival (OS) in the validation dataset from TCGA.
(hsa-miR-509-3p = 0.575, hsa-miR-769-3p = 0.599, hsa-miR-671-3p = 0.569, hsa-miR-296-5p = 0.568, hsa-miR-767-5p = 0.469, hsa-miR-421 = 0.573, hsa-miR-193a-3p = 0.554, hsa-miR-139-3p = 0.546, hsa-miR-342-3p = 0.54, hsa-miR-193a-5p = 0.57). This result showed that the combination of these 10 miRNAs had better capability to predict postoperative recurrence in HCC patients than the single miRNAs (Fig. 5A). Additionally, Kaplan–Meier survival analysis was utilized to evaluate patient DFS between the high-risk group and the low-risk group, with the former having a much greater recurrence rate than the latter (Fig. 5E).

The same result was verified again in the internal validation dataset from TCGA, which showed that the combination of the 10 miRNAs had the best predictive ability for recurrence after surgery (AUC = 0.72) (Fig. 5B). The AUC values for hsa-miR-509-3p, hsa-miR-769-3p, hsa-miR-671-3p, hsa-miR-296-5p, hsa-miR-767-5p, hsa-miR-421, hsa-miR-193a-3p, hsa-miR-139-3p, and hsa-miR-193a-5p were 0.634, 0.527, 0.665, 0.589, 0.541, 0.566, 0.649, 0.519, 0.52, and 0.633, respectively (Fig. 5B). In the validation set, the combination of the 10 miRNAs still had the best postoperative recurrence prediction capability. As with the training dataset from TCGA, Kaplan–Meier survival analysis was used to compare the difference in DFI between the high- and low-risk groups, and the results showed a higher recurrence rate in the former (Fig. 5F).

In addition to surgery, liver transplantation is an important treatment for HCC, though recurrence after liver transplantation is an important factor affecting the survival time of patients. To further validate the ability of the 10 miRNAs to predict HCC recurrence in patients after liver transplantation, we used GSE30297 as an external validation dataset. Surprisingly, these 10 miRNAs were also able to accurately predict liver cancer recurrence after liver transplantation (AUC = 0.702) (Fig. 5C). Again, the combination of the 10 miRNAs was able to predict recurrence after liver transplantation more accurately than any single miRNA (Fig. 5C).

In summary, the logistic regression formula constructed from 10 miRNAs was able to accurately predict tumor recurrence in postresection and posttransplantation HCC patients and performed well in TCGA training, TCGA internal validation, and GSE30297 external validation datasets (Fig. 5D).

**Multivariate Cox regression for overall survival prediction**

The logistic regression model constructed with the 10 miRNAs was able to accurately predict tumor recurrence after liver resection and liver transplantation, and the risk score correlated with DFI in patients with HCC (Fig. 1B). To further validate the ability of the 10 miRNAs to predict survival in HCC patients, we constructed a multivariate Cox regression model (Fig. 1B).

Multivariate regression analysis showed that combination of hsa-miR-509-3p (HR: 1.085, 95% CI 0.777–1.516; P = 0.631), hsa-miR-769-3p (HR: 0.752, 95% CI 0.386–1.464; P = 0.402), hsa-miR-671-3p (HR: 2.613, 95% CI 1.381–4.942; P = 0.003), hsa-miR-296-5p (HR: 0.877, 95% CI 0.644–1.194; P = 0.403), hsa-miR-767-5p (HR: 1.03, 95% CI 0.911–1.165; P = 0.638), hsa-miR-421 (HR: 1.097, 95% CI 0.658–1.798; P = 0.744), hsa-miR-193a-3p (HR: 1.702, 95% CI 0.864–3.355; P = 0.124), hsa-miR-139-3p (HR: 0.677, 95% CI 0.478–0.959; P = 0.028), hsa-miR-342-3p (HR: 1.102, 95% CI 0.785–1.548; P = 0.574), and hsa-miR-193a-5p (HR: 0.583, 95% CI 0.28–1.215; P = 0.15) was
a prognostic factor in HCC. Multivariate regression risk scores were calculated using the following formula: the combination miRNA panel = (0.082 × expression of hsa-miR-509-3p) + (−0.285 × expression of hsa-miR-769-3p) + (0.96 × expression of hsa-miR-671-3p) + (−0.132 × expression of hsa-miR-296-5p) + (0.03 × expression of hsa-miR-767-5p) + (0.0839 × expression of hsa-miR-421) + (0.532 × expression of hsa-miR-193a-3p) + (−0.39 × expression of hsa-miR-139-3p) + (0.097 × expression of hsa-miR-342-3p) + (−0.539 × expression of hsa-miR-193a-5p). Multivariate Cox regression analysis showed that miRNAs with HR values less than 1 were negatively associated with OS, which was different from the results of Kaplan–Meier analysis for the individual miRNAs (Fig. 4B).

Fig. 6 The role of the 10-miRNA combination in prognostic assessment of HCC patients. A ROC curves showed that the Cox regression model constructed using these 10 miRNAs in the training dataset from TCGA could well predict the prognosis of HCC patients. B ROC curves showed that this 10-miRNA combination also performed well in the validation dataset from TCGA. C Kaplan–Meier survival analysis estimates of the OS of HCC patients according to risk scores calculated with this 10-miRNA combination in the training dataset. D Kaplan–Meier survival analysis estimates of the OS of HCC patients according to the risk score calculated with this 10-miRNA combination in the validation dataset.
Using the training dataset from TCGA, the combination of the 10 miRNAs was well able to predict the 3-year survival status of HCC patients (1 year = 0.65, 2 years = 0.75, and 3 years = 0.75) (Fig. 6A). The Kaplan–Meier curve showed that patients in the high-risk subgroup had worse prognosis (Fig. 6C).

The same conclusion was confirmed in the internal validation dataset from TCGA. The ROC curve showed the combination of the 10 miRNAs to be a desirable predictor of overall survival outcome (1 year = 0.66, 2 years = 0.69, and 3 years = 0.68) (Fig. 6B). Patients were divided into high-risk and low-risk groups according to risk score, and survival analysis suggested that the high-risk group had a significantly higher death rate than the low-risk group (Fig. 6D).

In conclusion, these 10 miRNAs were also good predictors of overall survival in patients with HCC. A multivariate Cox regression model constructed with these 10 miRNAs to calculate risk score was able to assess the prognosis of HCC patients.

Identification of the functions of the 10 miRNAs.

Because these 10 miRNAs are associated with the prognosis of liver cancer patients, exploring their functions is crucial for subsequent studies. Binding partners for these 10 miRNAs were predicted using the StarBase database, and then clusterProfiler was used for Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis (Fig. 7). Functional analysis showed the 10 miRNAs to be enriched in autophagy, hepatocellular carcinoma, the ErbB signaling pathway, and the mTOR signaling pathway, as shown in the bubble chart in Fig. 7.

This result suggests that these 10 miRNAs might influence the biological process of HCC through these tumor-associated pathways, providing a basis for molecular-level studies.

![Results of functional analysis of 10 miRNAs. A Flowchart of functional analysis. B Bubble chart showing the top 20 pathways related to the 10 miRNAs](image)
Discussion

In this study, we identified 10 miRNAs associated with HCC recurrence and prognosis. The accuracy of these 10 miRNAs to predict tumor recurrence after surgery or liver transplantation in patients with HCC was verified using an external validation dataset (GSE30297) and an internal validation dataset (TCGA). Multiple previous studies have shown that these 10 miRNAs are associated with multiple malignancies, including hepatocellular carcinoma, gastric cancer, and pancreatic ductal adenocarcinoma [12–14].

These 10 miRNAs can accurately predict recurrence of hepatocellular carcinoma and, in addition, are associated with several tumor biological processes. Several miRNAs (such as hsa-miR-509-3p, hsa-miR-769-3p, and hsa-miR-342-3p) play a role in the inhibition of the proliferation, migration, invasion of breast cancer, glioma, and non-small cell lung cancer [15–17]. Multiple pathways are involved in the mechanism by which recurrence-associated miRNAs regulate malignancy progression, such as the tumor-associated pathways Wnt/β-catenin signaling pathway (hsa-miR-769-3p), ERK signaling (hsa-miR-193a-3p), and AKT-mTOR pathway (hsa-miR-193a-5p) [16, 18, 19]. These 10 miRNAs are also associated with drug resistance to antitumor drugs. For example, hsa-miR-509-3p regulates platinum drug sensitivity in ovarian cancer and osteosarcoma [20, 21]. A previous study suggested that hsa-miR-193a-5p plays a role in reducing 5-FU and oxaliplatin chemoresistance in colorectal cancer [22]. Our KEGG functional analysis results are consistent with previous studies showing that these miRNA-associated mRNAs are enriched in malignancy-related pathways such as hepatocellular carcinoma (hsa05225), pancreatic cancer (hsa05212), non-small cell lung cancer (hsa05223), and colorectal cancer (hsa05210).

For individual miRNAs, multiple previous studies have described their role in the recurrence and prognostic assessment of HCC. Levels of the oncogene hsa-miR-767-5p are significantly elevated in HCC tissues, and this high expression trend correlates with poor DFI and OS [23]. According to the results of our study, the expression level of hsa-miR-767-5p correlated negatively with prognosis. Another prognosis-related gene, hsa-miR-421, which is known as a tumor-promoting factor, was shown to be associated with worse prognosis in our study and a previous one [24]. However, there was a different trend for hsa-miR-296-5p. One study showed that higher expression of hsa-miR-296-5p is associated with a better prognosis, whereas our results indicated that high expression of hsa-miR-296-5p is associated with favorable DFI (P = 0.0027) but not with OS (P > 0.05) [25]. Similarly, there is inconsistency between a previous study and our findings for hsa-miR-342-3p [26]. More surprisingly, the findings of Kaplan–Meier survival analysis of DFI and OS were opposite in our study. The most obvious reason for these differences is that miRNAs play a pleiotropic role in cancer. The intricacy of the genetic network makes it probable that several important miRNAs, as opposed to just one, are required for tumor growth. Therefore, the stability and reproducibility of integrating multiple miRNAs for recurrence and prognosis assessment of HCC patients are better than with single miRNAs.

Because postoperative recurrence is an important factor affecting the survival of HCC patients, researchers have been attempting to find miRNA combinations to accurately predict postoperative recurrence. Bai et al. identified a 6-miRNA signature (including hsa-miR-210, hsa-miR-550a-1, hsa-miR-3199–2, hsa-miR-4732, hsa-miR-22, and
hsa-miR-139) to predict postoperative recurrence in patients with HCC [11]. Not only postoperative recurrence but also assessment of the prognosis of patients with HCC can guide clinicians in decisions. Based on imaging of vascular invasion and metastasis-related miRNAs, investigators have determined that different miRNA combinations well predict the prognosis of liver cancer patients [10, 27]. These two studies coincide with our idea in terms of variable inclusion selection. The miRNAs they included were metastasis or vascular invasion-associated miRNAs and not miRNAs differentially expressed in tumor tissue and normal tissue. We also believe that screening variables for recurrence and prognosis assessment should focus on the full range of miRNAs, rather than on differential miRNA expression between tumor tissue and normal tissue. The differential expression profile of miRNAs between tumor tissue and normal tissue should be the focus of research on malignant tumor diagnosis [28].

One of the main concerns reflecting the greater mortality of HCC is a recurrence after liver transplantation. A previous study has shown that circulating exosomal miR-92b is a good predictor of HCC recurrence after liver transplantation [29]. For hepatitis B virus-mediated hepatocellular carcinoma, miR-21 is associated with post-translation tumor recurrence [30]. We verified the role of these 10 miRNAs in the prediction of HCC recurrence after liver transplantation in the validation dataset. This is a kind of double validation, that is, it not only confirms the predictive ability of postoperative recurrence of HCC, but also verifies the predictive ability of relapse after liver transplantation.

The focus of most studies on tumor diagnosis and prognosis has always been the selection process of variables. Excellent variable screening methods can help researchers remove noise in the data matrix and avoid overfitting of the model. In this study, Lasso regression and Gaussian mixed model were used for variable screening, and the results showed that the method we chose was well suited for our study. In addition to our method of choice, bioinformatics engineers are also looking for disease-relevant specific miRNA screening methods. Computational prediction models might efficiently explore the most likely candidates for additional validation trials as a useful supplement to experiment-based techniques, which are expensive and time-consuming, and so reduce the time and cost for miRNA-disease association detection. These prediction models may specifically be broken down into four groups: models based on score functions, complicated network algorithms, machine learning, and numerous biological information sources [31]. Our research did not compare the pros and cons of these methods with our innovative Lasso regression analysis combined with Gaussian mixed model variable screening method, which had certain limitations. In further research we will focus on these computational prediction models to screen out disease-specific miRNAs.

When clinicians are faced with brand-new sequencing data and want to screen out disease-related miRNAs, the first thought is to find differentially expressed miRNAs, and then functional enrichment analysis to find specific pathways or function-related miRNAs, and then proceed to the next experiment. The possible reasons for this phenomenon mainly include that clinicians are unfamiliar with the underlying algorithms and lack the ability to skillfully use advanced statistics. This study also has this limitation. In the variable screening step, in order to avoid the exclusion of too many miRNAs in differential analysis and functional enrichment analysis, which may cause some miRNAs
to be mistakenly considered as noises not related to disease, we included all miRNAs in
the variable screening process. In recent years, computer scientists and algorithm engi-
eers have developed many significant algorithmic models for predicting disease-related
miRNAs. This provides a new idea for clinicians to screen disease-related miRNAs. For
instance, a unique computational approach called Ensemble of Decision Tree based
MiRNA-Disease Association prediction (EDTMDA) develops a computational frame-
work for ensemble learning and dimensionality reduction, which can precisely screen
certain disease-related miRNAs [32]. The computer approach of integrating heterogene-
ous biological data to anticipate probable correlations can significantly reduce time and
money when compared to traditional biological tests. Deep-belief network for miRNA-
disease association prediction model (DBNMDA) was developed by researchers. It
used feature vectors to pre-train restricted Boltzmann machines for all miRNA-disease
pairs and applied positive samples and the same number of selected negative samples
to fine-tune DBN to produce the final predicted scores [33]. In addition, a brand-new
computational model called Neighborhood Constraint Matrix Completion for MiRNA-
Disease Association prediction (NCMCMMDA) has been developed, whose basic theory
is to recover the missing miRNA-disease associations based on the known miRNA-dis-
ease associations and integrated disease (miRNA) similarity [34]. These disease-related
miRNA screening methods based on complex algorithms and excellent prediction accu-
rracy provide clinicians with new options.

The prognosis of HCC, or the use of bioinformatics methods to build a predictive
model for predicting the overall survival or disease-free survival of patients with
HCC, is currently the main focus of research on the screening of HCC-related diag-
nostic molecules based on public databases. Additionally, the Lasso regression analy-
sis is the primary variable screening technique. In this study, the prediction of HCC
recurrence—which is novel in other studies—includes the prediction of HCC recurrence
following liver transplantation. Lasso regression analysis and a Gaussian mixed model
were innovatively used in this study’s variable screening, and the validation findings
demonstrate that the model created using this variable screening approach also per-
formed well in the validation dataset. However, there are certain drawbacks to our
study, the most significant of which is the lack of our own validation data in the inter-
nal and validation datasets, which were collected from public databases. In order to
build more advanced mathematical models for the diagnosis, prognosis, and recur-
rence of HCC patients, we will gather the clinical data of patients with HCC at our
facility and create our own sequencing database in the course of future research.

**Conclusion**

In conclusion, the combination of 10 miRNAs can accurately predict tumor recur-
rence in HCC patients after surgery and liver transplantation. Moreover, these 10
miRNAs also play a guiding role in the prognosis evaluation of HCC patients. Further
studies are required to validate our recurrence and prognosis assessment model using
a large-scale validation dataset, and to confirm the biological functions of these 10
miRNAs through in vivo and in vitro experiments.
Acknowledgements
We would like to thank the peer reviewers and editors for their work, which helped us to significantly improve the quality of the manuscript.

Author contributions
Z-XF: Research design, data analysis, manuscript writing. Z-D: Data collection. B-XF: Validation. Z-XH: Funding acquisition, manuscript revision. C-L: Project administration, manuscript revision. All authors read and approved the final manuscript.

Funding
This work is supported by the following grants: Xuzhou Key Research and Development Project (No. KC19192) and Xuzhou Key Research and Development Project (No. KC20124).

Availability of data and materials
The datasets used in this study were downloaded from GEO (https://www.ncbi.nlm.nih.gov/geo/) and UCSC xena (http://xena.ucsc.edu/). The R package used was obtained from Bioconductor (https://www.bioconductor.org/). All data generated or analyzed during this study are included in this published article. If readers have any questions about the data processing, please do not hesitate to contact us (Xuanfeng Zhang: zxfujs@126.com).

Declarations

Ethical approval and consent to participate
Ethical approval was not required for this study because we used a public database.

Consent for publication
Not applicable.

Competing interests
The authors have declared that no competing interest exists.

Received: 18 July 2022   Accepted: 7 November 2022

Published online: 14 November 2022

References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.
2. Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tribelli C, Bellentani S. Group H-NIS: clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63(3):827–38.
3. Chang YJ, Chung KP, Chang YJ, Chen L.J. Long-term survival of patients undergoing liver resection for very large hepatocellular carcinomas. Br J Surg. 2016;103(11):1513–20.
4. Mazzaferrero V, Regalia E, Doci R, Andreola S, Pulvirenti A, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):691–9.
5. Peng ZW, Lin XL, Zhang YJ, Liang HH, Guo RP, Shi M, Chen MS. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology. 2012;262(3):1022–33.
6. Chen PJ, Chen DS, Lai MY, Chang MH, Huang GT, Yang PM, Sheu JC, Lee SC, Hsu HC, Sung JL. Clonal origin of recurrent hepatocellular carcinomas. Gastroenterology. 1989;96(2 Pt 1):527–9.
7. Emidge S, Pucher PH, Markar SR, Malietzis G, Athanasiou T, Darzi A, Sodergren MH, Xiao LR. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma. Br J Surg. 2017;104(11):1433–42.
8. Mazzaferrero V, Sposito C, Zhou J, Pinna AD, De Carolis L, Fan J, Cescon M, Di Sandro S, Yi-Feng H, Lauterio A, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology. 2018;154(1):128–39.
9. Filgueira NA. Hepatocellular carcinoma recurrence after liver transplantation: risk factors, screening and clinical presentation. World J Hepatol. 2019;11(13):261–72.
10. Luo L, Li Y, Huang C, Lin Y, Su Y, Cen H, Chen Y, Peng S, Ren T, Xie R, et al. A new 7-gene survival score assay for pancreatic cancer patient prognosis prediction. Am J Cancer Res. 2021;11(2):495–512.
11. Bai F, Zhou H, Ma M, Guan C, Liu J, Meng QH. A novel RNA sequencing-based miRNA signature predicts with recurrence and outcome of hepatocellular carcinoma. Mol Oncol. 2018;12(7):1125–37.
12. Zhang H, Liu S, Chen L, Sheng Y, Luo W, Zhao G. MicroRNA miR-509-3p inhibit metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma. Bioengineered. 2021;12(1):2263–73.
13. Dai W, Liu S, Zhang J, Pei M, Xiao Y, Li J, Hong L, Lin J, Wang J, Wu X, et al. Viral oncoprotein triggers miR-186-3p-mediated suppression of proliferation and induces apoptosis via the STAT3-IGF1R-HDAC3 complex in human gastric cancer. Cancer Lett. 2021;521:196–209.
14. Liu Y, Shi M, He X, Cao Y, Liu P, Li F, Zou S, Wen C, Zhan Q, Xu Z, et al. LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and 6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2022;15(1):52.
15. Wu D, Jia H, Zhang Z, Li S. Circ-PRMT5 promotes breast cancer by the miR-509-3p/TCF7L2 axis activating the PI3K/AKT pathway. J Gene Med. 2021;23(2):e3300.
16. Wang K, Yang S, Gao Y, Zhang C, Su Q. MicroRNA-769-3p inhibits tumor progression in glioma by suppressing ZEB2 and inhibiting the Wnt/beta-catenin signaling pathway. Oncol Lett. 2020;19(1):992–1000.
17. Xue X, Fei X, Hou W, Zhang Y, Liu L, Hu R. miR-342-3p suppresses cell proliferation and migration by targeting AGR2 in non-small cell lung cancer. Cancer Lett. 2018;412:170–8.
18. Yang G, Xu Q, Wan Y, Zhang L, Wang Z, Meng F. miR-193a-3p enhanced the chemosensitivity to trastuzumab in gallbladder carcinoma by targeting KRAS and downregulating ERK signaling. Cancer Biother Radiopharm. 2021;24:744.
19. Xu H, Liu Y, Cheng P, Wang C, Liu Y, Zhou W, Xu Y, Ji G. CircRNA_0000392 promotes colorectal cancer progression through the miR-193a-3p/PKIR3R/3'UTR axis. J Exp Clin Cancer Res. 2020;39(1):283.
20. Niu L, Ni H, Hou Y, Du Q, Li H. miR-509-3p enhances platinum drug sensitivity in ovarian cancer. Gene. 2019;666:63–7.
21. Patil SL, Palat A, Pan R, Rajapakse K, Mirchandani R, Bondesson M, Yustein JT, Coarfa C, Gunaratne PH. MicroRNA-509-3p inhibits cellular migration, invasion, and proliferation, and sensitizes osteosarcoma to cisplatin. Sci Rep. 2019;9(1):19089.
22. Aazar M, Aghazadeh H, Mohammed HH, Sara MRS, Hosseini A, Shomali N, Tamjidi-Far R, Tarzi S, Mansouri M, Sarand SP, et al. miR-193a-3p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4. Int Immunopharmacol. 2021;92:107355.
23. Zhang L, Geng Z, Yan Y, Meng F, Meng X, Wang L. Functional analysis of miR-767-5p during the progression of hepatocellular carcinoma and the clinical relevance of its dysregulation. Histochem Cell Biol. 2020;154(2):231–43.
24. Xie Y, Wang L, Yue W, Zou H, Li K, Liu K, Zhao W, Zhu C, Cao J. Profiling and integrated analysis of differentially expressed microRNAs as novel biomarkers of hepatocellular carcinoma. Front Oncol. 2021;11:70918.
25. Shi DW, Li LX, Bian XY, Shi XJ, Lu LL, Zhou HK, Pan TJ, Zhou J, Fan J, Wu WZ. miR-296-5p suppresses EMT of hepatocellular carcinoma via attenuating NRG1/ERBB2/ERBB3 signaling. J Exp Clin Cancer Res. 2018;37(1):294.
26. Gao Y, Zhang SG, Wang ZH, Liao JC. Down-regulation of miR-342-3p in hepatocellular carcinoma tissues and its prognostic significance. Eur Rev Med Pharmacol Sci. 2017;21(9):2098–102.
27. Chen W, Wang H, Li T, Liu T, Yang W, Jin A, Ding L, Zhang C, Pan B, Guo W, et al. A novel prognostic model for hepatocellular carcinoma based on 5 microRNAs related to vascular invasion. BMC Med Genom. 2022;15(1):34.
28. Yu B, Zhou S, Liang H, Ye Q, Wang Y. Development and validation of a novel circulating miRNA-based diagnostic score for early detection of hepatocellular carcinoma. Dig Dis Sci. 2022;67(6):2283–92.
29. Nakano T, Chen H, Wang CC, Chen PJ, Tseng HP, Huang KT, Hu TH, Li LC, Goto S, Cheng YF, et al. Circulating exosomal miR-92b: its role for cancer immunoediting and clinical value for prediction of posttransplant hepatocellular carcinoma recurrence. Ann J Transpl. 2019;19(12):3250–62.
30. Dundar HZ, Aksoy F, Aksoy SA, Tasar P, Ugras N, Tunca B, Egeli U, Cecener G, Yerci O, Kaya E. Overexpression of miR-21 is associated with recurrence in patients with hepatitis B virus-mediated hepatocellular carcinoma undergoing liver transplantation. Transpl Proc. 2019;51(4):1157–61.
31. Chen X, Xie D, Zhao Q, You ZH. MicroRNAs and complex diseases: from experimental results to computational models. Brief Bioinform. 2019;20(2):515–39.
32. Chen X, Zhu CC, Yin J. Ensemble of decision tree reveals potential miRNA-disease associations. PLoS Comput Biol. 2019;15(7):e1007209.
33. Chen X, Li TH, Zhao Y, Wang CC, Zhu CC. Deep-belief network for predicting potential miRNA-disease associations. Brief Bioinform. 2021;22(3):774.
34. Chen X, Sun LG, Zhao Y. NOMI-CMDA: miRNA-disease association prediction through neighborhood constraint matrix completion. Brief Bioinform. 2021;22(1):485–96.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.